|Videos|July 15, 2016

How Does the Hospital Environment Impact Susceptibility to HAIs in Special Populations?

Michael Calderwood, MD, MPH, previously an assistant hospital epidemiologist and associate director of antimicrobial stewardship at Brigham and Women’s Hospital, discusses how the hospital environment can be dangerous to special population patients.

Michael Calderwood, MD, MPH, previously an assistant hospital epidemiologist and associate director of antimicrobial stewardship at Brigham and Women’s Hospital, discusses how the hospital environment can be dangerous to special population patients.

Interview Transcript (slightly modified for readability)

“Something that often comes up with having new buildings being constructed is, [with] every good intention, we have people who want to put up decorative things, whether that be a green wall with plants that are going to require irrigation or a waterfall or fountain. We always have to be careful of the unintended consequences of such things in the hospital setting.

In particular, we are [constructing] buildings that are now going to be ambulatory in-patient care centers for some of our most vulnerable patients. [Therefore], We have to be thoughtful that while [decorations] are pretty, they might actually pose a risk to the patient population.”


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.